1. X. Wu, L. Xia,et al. Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy for recurrent or metastatic cervical cancer. 2024 SGO
3. Xia L, Zhou Q, Gao Y, et al. A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma. Nat Commun. 2022;13(1):7581. Published 2022 Dec 8. doi:10.1038/s41467-022-35133-4
4. X. Wu, L. Xia,et al. Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer. 2023 ESMO. LBA44